[1] |
CHEN Siying, DING Xueli, LIU Shujia, ZHANG Xiaomeng, ZHANG Bing, LIN Zhijian.
Modeling for Prediction of Cardiotoxicity of Chinese Herbal Medicines
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 869-875.
|
[2] |
WANG Chunting, CHEN Yafei.
Considerations for Revision of Safety Information in the Post-Marketing Instructions of Chemical Drugs
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 776-779.
|
[3] |
LI Dong, SONG Yana, WANG Ligang, BIAN Rongrong, ZHAO Yan.
Considerations for Establishing National Sentinel Hospitals for Medical Device Adverse Event Monitoring
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 780-785.
|
[4] |
LI Dong, ZHAO Yan.
Roles of National Arthroplasty Registries in Post-Market Surveillance of Medical Devices
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(6): 640-644.
|
[5] |
LIU Ying, XIONG Shunyu, XIONG Huiyu, CAI Fei, XU Mengdan, WANG Qing, REN Wei, XU Yan.
Methods for Assessment of MAH Compliance with GVP
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 282-285.
|
[6] |
ZHONG Ling, ZENG Huiyan, YUAN Xin, WANG Yingyan.
Adverse Event Signals of Liraglutide and Semaglutide Based on the FAERS Database
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 305-312.
|
[7] |
ZHU Lan, SHAO Bo, ZHU Yan, DAI Jie, ZHONG Shiqi.
Current Progress and Considerations in Updating the Safety Information in Labels of Chinese Traditional Patent Medicines
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(2): 188-192.
|
[8] |
NIE Xiaolu, ZHAO Houyu, HUO Donghui, YAN Aixia, SUN Feng, PENG Xiaoxia, NI Xin, ZHAN Siyan.
Pediatric Drug-Induced Immune Thrombocytopenia Based on Real World Data and Quantitative Structure-Activity Relationship
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 16-22.
|
[9] |
WANG Tao, SONG Haibo, WANG Qing, HOU Yongfang, LIU Hongliang, ZHANG Lin.
Brief introduction and inspiration to the WHO guidance on Ethics and Governance of Artificial Intelligence for Health
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 906-909.
|
[10] |
YAO Weijie, YAN Shiqi, YUAN Sisi, GONG Leilei, FENG Xin.
Roles of Yangxue Antai prescription in improving endometrial epithelial-mesenchymal transformation and decidualization in recurrent spontaneous abortion mice by regulating autophagy
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(5): 547-552.
|
[11] |
HAN Li, CHEN Li, CHEN Qian, XIAO Hongtao.
Signal detection of adverse reaction of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir based on FAERS database
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(4): 440-446.
|
[12] |
WANG Shan, XIE Bo, LIU Huimin, LI Zhihao.
Adverse event signals for celecoxib based on FAERS database
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 190-194.
|
[13] |
ZHANG Yu, ZHANG Wei, GAO Shuangrong, CHEN Mengping, WANG Yaxin, XU Yingli, CAO Shan, ZHAO Ronghua, BAO Lei, LI Shuran, SUN Jing, BAO Yanyan, GENG Zihan, GUO Shanshan, JI Zuen, CUI Xiaolan.
Screening and analysis of host factors interacting with NS1 proteins of influenza A virus based on the proteome chip
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 40-44.
|
[14] |
XIONG Weiyi, REN Jingtian.
Considerations for revision of safety information in package inserts of anti-cancer drugs in post-market phase
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 94-97.
|
[15] |
ZHANG Qi, CHEN Min, ZHANG Shiqing.
Conditional approval of medical devices in the United States and enlightenment
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1007-1010.
|